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1. Introduction  
Uterine leiomyoma and adenomyosis represent the most common benign tumors of the female 
reproductive system (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 2008). These tumors 
are estrogen dependent, develop during the reproductive period, and are suppressed with 
menopause. Traditional treatments for myomas and adenomyosis have been various types of 
surgical techniques. Medical management of these tumors is an approach that has been used 
recently and is attractive for many gynecologists because of its relative ease and lack of 
complications (pelvic organ adhesion) compared with surgery.  Indications for therapy are 
similar to those for surgical removal of these tumors and focus on preserving fertility and/or 
the patient’s desire to maintain her uterus. Medications used include androgens, 
antiprogestogens (mifepristone), raloxifen, and gonadotropin-releasing hormone agonist 
(GnRHa) (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 2008; Schweppe, 1999). At present, 
considering efficiency and safety issues, none of the above agents obtained adequate 
popularity except for GnRHa. However, GnRHa also have disadvantages including bone loss 
and menopausal symptoms. The effect of GnRHa is transient and reversal of estrogen 
deprivation occurs soon after discontinuation of the GnRHa and most myoma and 
adenomyosis returns to their initial size within several months after discontinuation. 
Dienogest is a selective progestin that combines the pharmacologic properties of 19-
norprogestins and progesterone derivatives, offering potent progestogenic effects without 
androgenic, mineral corticoid, or glucocorticoid activity (Harada & Taniguchi, 2010; 
Sasagawa et al, 2008; Sitruk-Ware, 2006). Previous trials demonstrated that dienogest 
provides effective reductions in endometriosis-associated pelvic pain and laparoscopic 
measures of pathology (Harada et al, 2009; Köhler et al, 2010; Schindler et al, 2006; Strowitzki 
et al, 2010b). Recently, the new progesterone 2 mg daily demonstrated equivalent efficacy to 
GnRHa (e.g. buserelin acetate and leuprolide acetate) for relieving the pain of endometriosis 
in two 24-week, randomized studies (Harada et al, 2009; Strowitzki et al, 2010a; Strowitzki et 
al, 2010b). Because uterine myoma/adenomyosis and endometriosis have many common 
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features (Huang et al, 2010), these successful trials on endometriosis support that the use of 
dienogest inhibits myoma and adenomyosis growth. While evaluating superiority of 
dienogest in women with endometriosis, we have found significant shrinkage of myoma 
nodes coexisted with endometriosis over several months during an administration of 
dienogest (Ichigo et al, 2011). In this paper, we attempted to prevent their regrowth after 
discontinuation of GnRHa using dienogest. This retrospective study may be the first study 
that examined the efficacy and safety of dienogest following GnRHa therapy in 
perimenopausal women until leading to a natural menopause.  
2. Materials and methods 
2.1 Reproductive chart review 
The data were collected from 13 perimenopausal patients sequentially treated with leuprolide 
acetate (1.88mg monthly, Takeda Pharmaceutical, Japan) for 6 months and dienogest 
(2mg/day, Mochida Pharmaceutical, Japan) for 6 months against endometriosis in our patient 
clinic from January 2008 to May 2011. In this retrospective chart review, we included all 
perimenopausal patients complicated with a myoma node measuring > 4cm or with 
adenomyosis measuring >10 cm at the age 46-52 years. Measurements of nodes or total uterine 
volume using MRI were performed at baseline and during treatment at months 6 and 12.  For 
tecknical reasons, leuprolide acetate was supplied in vials and dienogest in tablets. 
Size of myoma or overall uterine was measured at three diameters (transverse, vertical and 
anterior-posterior) with MRI.  Half of multiplied three diameters was accepted as size of 
myomas and uterus. These measurements were repeated 6 and 12 months after starting the 
therapy.  
2.2 Statistics 
Pared t-tests were used to analyze in each size change from baseline.  Statitstical significance 
was defined as P < 0.05. 
 
Case No. 
Age 
(years) 
Myoma type 
Total myoma volume (cm3) 
(% of baseline)
Baseline 
After GnRHa 
treatment
After dienogest 
treatment 
1 48 Intramural 108.6 78.6 (72.2) 80.6 (74.0) 
2 49 Intramural 72.8 61.9 (85.0) 58.6 (80.5) 
3 46 
Intramural
(multiple)
45.6 33.6 (73.7) 36.9 (80.9) 
4 52 
Intramural
(multiple)
89.3 42.7 (47.8) 50.9 (57.0) 
5# 52 Adenomyosis 117.5 56.3 (47.8) 50.3 (42.8) 
6 50 Subserosal 88.7 85.6 (96.5) 81.7 (92.1) 
7## 52 
Subserosal
(multiple)
87.2 43.6 (50.0) 45.2 (51.8) 
Average  49.9 ± 2.3 87.1 ± 23.5 
57.5 ± 19.3*
(67.6 ± 19.5)
57.7 ± 17.3* 
(68.4 ± 18.1) 
Table 1. Myoma volume change during sequential treatment with GnRHa and dienogest 
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The patients were sequentially treated with leuprolide acetate (1.88mg monthly) for 6 
months and dienogest (2mg daily) for 6months. Measurements of nodes using MRI were 
performed at baseline, during treatment at months 6 (after GnRHa therapy) and 12 (after 
dienogest therapy). 
# MRI changes of case 5 are presented as a representative prolile in Fig.1. 
## Case 7 was submitted to laparotomy at month 8 because of bilateral ovarian abscess.  See 
Fig. 2. 
* P < 0.01 versus baseline. 
 
 
Fig. 1. Total uterine volume change in the patient with myoma during sequential treatment 
with GnRHa and dienogest (case 6 of Table 1).  
The patient was sequentially treated with leuprolide acetate (1.88mg monthly) for 6 months 
and dienogest (2mg daily) for 6months. Sagittal T2-weighed MR imagings before (a), 
months 6 (after GnRHa therapy) (b) and 12 (after dienogest therapy)(c) 
3. Results 
Of 13 endometriosis patients sequentially treated with GnRHa and dienogest, 7 were 
associated with coexistent myoma node and adenomyosis; 4 intramural and 2 subserosal 
types and 1 of adenomyosis. Mean age was 49.9 ± 2.3 (46-52)(Table 1). Volume changes of 
total myoma and adenomyosis are presented as the percentage change from baseline in 
Table 1. A remarkable reduction in myoma /adenomyosis volume from baseline was noted: 
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the total volume of myoma/adenomyosis declined to 67.6 ± 19.5 % after GnRHa treatment 
table 1). During the dienogest-period, myoma volume remained as they shrunk; no 
regrowth occurred. Fig. 1 showed as a representative profile (case 6 of Table 1). One patient 
(case 7) discontinued therapy because of an unexpected event, onset on ovarian abscess 
developed in the endometrioma (see Fig.2). 
 
 
Fig. 2. Bilateral de novo ovarian abscesses in a 52-year-old woman with multilobular uterine 
myoma and bilateral ovarian endometriomas (case 7, table 1).  
The patient was treated with leuprolide acetate (1.88mg monthly, Takeda Pharmaceutical, 
Japan) for 6 months. Axial T2-weighed MR imagings before (a) and after (b) GnRHa 
treatment showed remarkable shrinkage of uterine myoma and bilateral endometriomas. An 
attempt to prevent the recurrence submitted the patient to dienogest therapy (2mg daily, 
Mochida Pharmaceutical, Japan). After two months, she complaint a one-week history of 
increasing abdominal girth and a two-day history of fever. Axial T2-weighed MR imaging 
(c) showed two enlarged cystic lesions, one in the left adnexa and the other in the right 
adnexa.  Both lesions were superimposed on the endometrioma with inhomogenous content 
and the thick wall, while shrunk uterine myoma was detected. There was no history of 
gynecological interventions including endometrioma aspiration, no had she ever used an 
intra-uterine device. The clinical and imaging findings and unresponsive to antibiotic 
therapy proposed the ovarian abscess developed in the endometriomas. At laparotomy, 
both ovarian cysts were markedly distended and filled with yellow-brown pus, and both 
ovaries were destroyed by multiple abscess pockets. Histology of the abscess wall confirmed 
endometriotic nature of the cyst. 
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4. Discussion 
Uterine myoma/adenomyosis and endometriosis have many common features. Both are 
estrogen-dependent conditions that can often be the source of pelvic pain and menstrual 
abnormalities. In addition, both have range of symptom severity that is often poorly 
correlated to preoperative or operative findings, making surgical planning a challenge 
(Huang et al, 2010). Recently we found significant shrinkage of myoma nodes coexisted with 
endometriosis over several months during an administration of dienogest (Ichigo et al, 
2011). To our knowledge this retrospective study may be the first study that examined the 
efficacy and safety of sequential management with dienogest following GnRHa therapy in 
perimenopausal women until leading to a natural menopause. 
Many studies have reported the potential usefulness of the hypoestrogenic state induced by 
GnRHa for treatment of uterine myoma (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 
2008). A GnRHa down-regulates the pituitary-ovarian-gonadal axis, leading to suppression 
of ovarian steroidogenesis.  In the present study our patients revealed an average reduction 
of 57.5 % in myoma volume in response to leuprolide acetae (1.8mg/month). The results are 
in agreement with those of previous studies (Levy, 2008; Parker, 2007; Parsanezhad et al, 
2010; Sankaran & Manyonda, 2008). The GnRHa treatment is often associated with so-called 
ovarian defect symptoms, including vasomotor instability, vaginal dryness, and significant 
bone loss, which preclude the long-term use of this compound (Levy, 2008; Parker, 2007; 
Sankaran & Manyonda, 2008). These limit the standard use of GnRHa to 6 months.  The 
regression of uterine or endometriosis volume is not permanent, with returning to their 
original size or even enlarging more rapidly upon cessation of GnRHa administration. 
GnRHa, therefore, can only be used in the short term, as temporizing measures in the 
perimenopausal woman, or pre-operatively to reduce myoma size, influence the type of 
surgery, restore hemoglobin levels and apparently reduce blood loss at operation (Sankaran 
& Manyonda, 2008).  
There may be profound differences among the available progestins according to their 
structure, metabolites and pharmacodynamic actions (Harada & Taniguchi, 2010; Sasagawa et 
al, 2008; Sitruk-Ware, 2006). It is therefore inappropriate to consider the various effects of the 
older and newer progestins as class effects. While it has long been established that estrogen 
promotes myoma growth, many biochemical and clinical studies suggested that older 
progestins, without an estrogen component, may be effective in the treatment of 
endometriosis, but not adenomyosis or myomas (Levy, 2008; Parker, 2007; Sankaran & 
Manyonda, 2008). The newer progestin dienogest demonstrates a modest suppression of 
estradiol, representing a potential advantage over other therapies, such as GnRHa, which 
require estrogen add-back if used longer than 6 months (Harada & Taniguchi, 2010; Strowitzki 
et al, 2010a). Also in contrast to GnRHa, dienogest is not associated with an increased incidence 
of hot flashes (Strowitzki et al, 2010a; Strowitzki et al, 2010b). More recently the efficacy and 
safety of long-term usage of dienogest have been demonstrated in previous controlled studies 
in a large number of patients with endometriosis (Endrikat et al, 2007; Momoeda et al, 2009; 
Schindler et al, 2010; Sitruk-Ware, 2006). Our previous paper demonstrated that the use of 
dienogest have several advantages over GnRHa therapy to manage uterine myoma (Ichigo et 
al, 2011). Management of uterine myoma using dienogest is useful in women for whom 
temporary reduction in myoma volume is aimed and no surgical intervention is planned for 
any reason. Women with uterine myoma who have pain, pressure effect, hypermenorrhea, or 
other types of abnormal uterine bleeding who wish to retain the option of childbirth; women 
who wish to save their uterus; women who are not fit for surgical intervention; and young 
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women with infertility can take advantage of this type of treatment. However, the total decline 
in myoma volume and controlling symptoms are greater in GnRHa protocol (Ichigo et al, 
2011). The benefit of dienogest in controlling symptoms may persist after therapy of GnRHa in 
perimenopausal women. 
In the previous study (Imai et al, 2003), because rapid regrowth frequently occurs after the 
therapy is stopped. we attempted to determine whether GnRHa therapy could lead 
perimenopausal women carrying symptomatic myomas to the natural onset of the 
menopause. A retrospective analysis of 145 patients who received GnRHa for 24 weeks 
demonstrated that after cessation of therapy no menstruation occurred over 25 weeks in 
women aged over 45 years, with elevated levels of follicle-stimulating hormone (FSH) and 
luteinising hormone (LH). To extend this observation, we studied prospectively 21 women, 
aged 45 years and older who had regular menstruation with symptoms attributed to 
myomas and elevated days 3 - 5 FSH and days 3 - 5 LH levels (> 25 mIU/ml). After 
discontinuation of GnRHa (leuprorelin acetate, 1.88 mg) therapy for 6 months, menstruation 
occurred in only two of 21 individuals but the remaining 19 cases had no menstrual 
bleeding. It is suggested that the rise in early follicular phase serum gonadotrophins, in 
particular FSH (> 25 mIU/ml), may precede the natural menopause following (or during) 
GnRHa therapy in older women. Measuring days 3 to 5 serum FSH concentrations may 
make it easier to decide on the optimal duration of therapy for symptomatic uterine fibroids 
in perimenopausal women aged > 45 years. However, in other words, approximately 10 % 
of women failed to become natural menopause. 
Regarding an unexpected event of case 7 of table 1, she has no known previous history of 
pelvic inflammatory disease, IUD, or any surgical intervention, so she was very unlikely to 
present with ovarian abscess.  It shows that an isolated ovarian abscess can develop in an 
endometrioma without any recognized risk factor.  There are different theories about 
developing an abscess in the endometrioma (Hameed et al, 2010; Kavoussi et al, 2006). It may 
be due to an altered immune environment within endometrial glands and stroma. Recent 
studies have shown that progesterone-like substances enhance the sexual transmission of 
various pathogens, including bacteria (Huber & Gruber, 2001; Vassiliadou et al, 1999). 
Collection of altered menstrual type of blood in a cystic space in the ovary and can be a 
suitable culture medium for pathogens. Cystic wall of endometrioma is theoretically weak 
as compared to normal ovarian epithelium, so it is susceptible to bacterial invasion. 
Lastly, we reported successful management of a series of patients with uterine myoma 
associated with endometriosis by sequential therapy with GnRHa and a progestine 
dienogest, although based on the finding in patients associated with endometriosis. The 
follow-up period of our study was too short to consider the recurrence rate of myomas after 
discontinuation of treatment in all subjects. Although prospective controlled study should 
be addressed, the use of dienogest treatment following GnRHa discontinuation for 
perimenopausal women with symptomatic uterine myoma or adenomyosis should be 
considered before choosing a more invasive interventions. 
5. Conclusion 
High recurrence rate rapidly after finishing GnRHa leads us to examine the efficacy of 
sequential management with GnRHa and dienogest in perimenopausal women with 
endometrisosis-associated uterine myoma. Consideration of GnRHa advantages on myoma 
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shrinkage and low incidence of dienogest-induced adverse events may lead to long-term 
management of perimenopausal women with myoma and adenomyosis.  
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